Accuray Inc.

CyberKnife S7 system (Image from Accuray)

Accuray (NSDQ:ARAY) announced today that long-term follow-up data demonstrated pain relief after image-guided robotic radiosurgery treatments with its CyberKnife system.

The data from a study of men and women with trigeminal neuralgia (TN) showed that 72% continued to experience pain relief 10 years after receiving the treatments delivered with the CyberKnife system.

“Robotic Image-Guided Radiosurgery for Trigeminal Neuralgia: Results after 10 Years,” the study abstract, was recognized as “Best Clinical Abstract” at the recent 2022 Radiosurgical Society Meeting in Carlsbad, California, according to a news release.

Sunnyvale, California-based Accuray designed the CyberKnife system to treat diseases in the head and base of the skull, as well as functional disorders, with radiosurgery, but without the use of a fixed frame bolted to the patient’s head.

The company said the system features a l…

Accuray (NSDQ:ARAY) shares dipped this morning despite second-quarter results that beat the consensus sales forecast.

The Sunnyvale, California-based radiation oncology company posted profits of $179,000, breaking even at $0.00 on earnings per share, on sales of $116.3 million for the three months ended Dec. 31, 2021, for a major bottom-line slide from profits of $4.8 million this time last year despite sales growth of 19.3%.

Accuray’s earnings per share of $0.00 equaled expectations on Wall Street, where analysts were looking for sales of $103.3 million.

“Accuray’s fiscal 2022 second-quarter performance continues to reflect the strong customer demand and revenue momentum our business is generating, but also highlighted global supply chain challenges and operational headwinds created by the Covid environment,” Accuray CEO Joshua Levine said in a news release. “Driving our accelerated revenue growth is the continued adoption …

Accuray (NSDQ:ARAY) shares were slightly down after hours today on first-quarter results that beat the consensus forecast.

The Sunnyvale, Calif.-based radiation oncology company posted losses of $1 million, or 1¢ per share, on sales of $107.4 million for the three months ended Sept. 30, 2021, seeing its bottom line slide into the red despite sales growth of 25.9%.

Accuray’s losses per share of 1¢ came in 5¢ ahead of Wall Street, where analysts were looking for sales of $93.9 million.

“By any measure, our Q1 performance was a very strong start to our FY22 fiscal year. Q1 revenue of $107.4 million represents the largest first fiscal quarter revenue that Accuray has ever recorded,” Accuray CEO Joshua Levine said in a news release. “Our performance reflects the visible impact of the investments in innovation we have made to our product portfolio, how those new technologies are being received by customers across the world and a laser-l…

Accuray (NSDQ:ARAY) shares dipped this morning despite fourth-quarter results that beat the consensus forecast.

The Sunnyvale, Calif.-based radiation oncology company posted losses of -$11.1 million, or -12¢ per share, on sales of $110.9 million for the three months ended June 30, 2021, for a massive bottom-line slide from losses of $152,000 this time last year despite sales growth of 16.8%.

Adjusted to exclude one-time items, earnings per share were -1¢, 1¢ ahead of Wall Street, where analysts were looking for sales of $102.1 million.

“Despite the challenging environment caused by the COVID-19 pandemic, we finished fiscal year 2021 on a strong note with 17% year-over-year revenue growth and 19% year-over-year gross order growth in the fourth quarter, both of which were ahead of our expectations,” Accuray CEO Josh Levine said in a news release. “I am proud of the team’s execution during the quarter and for the entire year, conside…

Accuray (NSDQ:ARAY) today said it has appointed Jean-Philippe Pignol as its chief medical and technology officer, effective April 15.

Pignol will lead the company’s scientific and clinical research activities, develop strategic collaborations, evaluate new technologies and serve as the representative with important industry partners.

“We’re thrilled to welcome Dr. Pignol, whose rich and unique experience base within the global radiation therapy community will help the Accuray team to achieve its vision of ‘expanding the curative power of radiation therapy.’ He joins the company at an important time in its growth and is a key addition to our executive leadership team,” president and CEO Joshua Levine said in a news release.

Pignol has more than 26 years of experience in academia and clinical practice. He has served as the professor and department head of radiation oncology at Dalhousie University in Halifax, Canada.

…

Accuray (NSDQ:ARAY) yesterday posted second-quarter results that beat the consensus forecast on Wall Street.

The Sunnyvale, Calif.-based company reported profits of $4.8 million, or 5¢ per share, on sales of $97.5 million for the three months ended Dec. 31, 2020, for a bottom-line slide of -55.5% sales loss of -1.4% compared with Q2 2020.

Earnings per share were 5¢, 9¢ ahead of The Street, where analysts were looking for sales of $92.4 million.

“Our second-quarter performance continues to reflect the positive momentum our business is making despite the headwinds created by the COVID-19 environment,” president and CEO Josh Levine said in a news release. “Highlights from our second quarter performance include the beginning of system revenue conversion related to the Type A radiotherapy licenses in China as well as receiving 510(k) FDA clearance of our ClearRT Helical kVCT Imaging platform for the Radixact System. We are pleased with the continued res…

Accuray (NSDQ:ARAY) shares took a hit today on fourth-quarter results that were mixed compared to the consensus forecast.

The Sunnyvale, Calif.-based radiotherapy device maker posted losses of -$823,000, or -1¢ per share, on sales of $94.98 million for the three months ended June 30, 2020, for a 41.2% bottom-line gain on a sales decline of -19.1%.

Accuray’s adjusted EPS of -1¢ came in 1¢ ahead of Wall Street projections, while its revenues missed the analysts’ projections by 4%.

“Despite the circumstances and the uncertainties associated with the COVID-19 pandemic, we finished fiscal 2020 with a solid performance and grew our gross orders by 10 percent year over year,” Accuray president & CEO Josh Levine said in a news release. “I am proud of the team’s execution during the quarter, especially given the challenging operating environment created by the pandemic. … We believe that our operational focus, joint venture strategy in…